Ironwood Pharmaceuticals Inc (IRWD) stock analysis

On Sep 24, 2026, our model rated Ironwood Pharmaceuticals Inc (IRWD) WEAK BUY with 28% confidence at a price of $4.33. That means the signals lean positive, but they are mixed, so conviction is low.

Technical picture

The 14-day RSI is 50, close to the neutral 50 line, so momentum is balanced.

MACD is above its signal line, a sign that short-term momentum is turning up.

The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.

Volume is about normal (0.9x the 20-day average).

Trend structure and money flow

Market structure: ranging / no clear structure.

The most recent swing high is $4.88 and the swing low is $2.95; traders often treat these as resistance and support.

Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.

Fundamentals

The company reports a profit margin of 33.4% and revenue growth of +32.6%.

In its latest quarter it earned $0.31 per share, which beat the $0.28 analysts expected, with revenue +32.6% year over year.

Wall Street's average rating is 2.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $6.10.

The next earnings report is expected around Nov 9, 2026; prices often move sharply around earnings.

Trade plan from the model

The model's long / bullish plan uses an entry near $4.19, a target of $4.58 (+9.3%) and a stop-loss at $3.82 (-8.8%).

That is a reward-to-risk ratio of about 1.1 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.

The plan has a time limit: reassess by Oct 4, 2026 whatever the price does.

The model's one-paragraph read

Leans BUY — composite score +0.28 (WEAK BUY). Technicals: RSI 50.0, MACD bullish, price above SMA50. Fundamentals: margin 33.4%, revenue growth 32.6%. Financial results: YoY revenue +32.6%, last EPS surprise +10.7%, next earnings 2026-11-09. Smart Money Concepts: ranging / no clear structure, price retesting a bearish order block. FinGPT news read: positive. Memory: 4 prior look(s); 100% of directional calls matched later price. Suggested levels: entry $4.19, target $4.58, stop-loss $3.82, exit by 2026-10-04 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).

Past ratings for IRWD

Of the last 4 directional calls on IRWD, 4 pointed the right way by the most recent analysis (100%). Past calls do not guarantee future results.

"Move since" compares each call's price with the latest analysed price.

Other Healthcare stocks we cover

JNJ · KMDA · LH · LLY · MDT · NRC · NVO · OSCR · PCRX · PGNY · PHR · PRGO

Frequently asked questions

Is IRWD a buy right now?

As of Sep 24, 2026, our automated model rates Ironwood Pharmaceuticals Inc (IRWD) WEAK BUY with 28% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.

What is the price target for IRWD?

The model's most recent plan targets $4.58 with a stop-loss at $3.82, from an entry near $4.19.

When does Ironwood Pharmaceuticals Inc report earnings next?

The next earnings report is expected around Nov 9, 2026.

What does a WEAK BUY rating mean?

A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.